Considering the suggestion from our previous study that 0.15 mg IVC was effective for Zone II Stage 2/3 ROP with plus disease,6 reducing the doses of the anti-VEGF agents appears to be a safer choice that reduces serum VEGF suppression. This evidence concerns the gene VEGFA and retinopathy of prematurity.